9650 Commerce Drive, Suite 521
About FAST BioMedical
FAST BioMedical is a clinical stage company advancing an innovative technology to measure Blood Volume. Blood Volume is relevant in patients with Congestive Heart Failure, Sepsis, Cardio-renal syndrome, and others in critical care. The technology has an FDA Expedited Review and has completed three human trials.
7 articles with FAST BioMedical
11/6/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
FAST BioMedical , a privately held late clinical-stage medical technology company, today announces it has named Jim Dillon to its Board of Directors. Dillon is a former St. Jude Medical and Abiomed executive, with significant experience capitalizing and commercializing first-in-class heart failure and cardiorenal syndrome
Steven Zelenkofske appointed chairman to provide expertise in heart failure clinical development. [17-September-2020] INDIANAPOLIS , Sept. 17, 2020 /PRNewswire/ -- FAST BioMedical , a late clinical-stage medical technology company, today announces establishing a Heart Failure Medical Advisory Board of world-recognized physicians, nurses and researchers. The Board w
6/26/2020Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
FAST BioMedical, a privately held late clinical-stage medical technology company, announces it has named Dr. Gregory B. Brown, M.D., M.B.A to its Board of Directors.
FAST BioMedical Announces Successful Completion of Multi-center Acute Congestive Heart Failure Trial in Germany
FAST BioMedical announced the completion of the EMPAKT-CHF clinical trial at Charité – Universitätsmedizin Berlin and Kerckhoff Klinik in Bad Nauheim.
FAST BioMedical has enrolled 20 patients in a clinical trial at Charité – Universitätsmedizin Berlin.